Michal Laniado Schwartzman

Michal Laniado Schwartzman is the chairman of pharmacology at New York Medical College. Michal is also a Ph.D. student at the college, exploring the relationship between 20-Hydroxyeicosatetraenoic acid (20-HETE), a cytochrome P450 (CYP) 4-derived arachidonic acid metabolite, and endothelial angiotensin converting enzyme (ACE) in human microvascular endothelial cells (HMVEC). Michal is also determining the contribution of 20-HETE and significance of ACE induction in the development of vascular remodeling and hypertension using various animal models of 20-HETE-dependent hypertension. Additionally, Schwartzman is developing and characterizing the novel water soluble 20-HETE antagonist (20-SOLA) and other compounds for the control and treatment of hypertension.

Michal Laniado Schwartzman attended Westtown School for their high school education. Michal then went on to Drew University where they earned their Bachelor of Arts in Biology. After Drew University, they attended the University of Medicine and Dentistry of New Jersey where they earned their Master of Science in Pharmacology. Lastly, they attended Yale University and New York Medical College where they earned their Doctor of Philosophy and completed their postdoctoral fellowship training in Pharmacology respectively.

Michal Laniado Schwartzman reports to Edward C. Halperin, Chancellor & CEO. They are on a team with Sandra A. Russo - Director, Nursing, Neil Schluger - Chairman, Medicine, and Lori A. Solomon - Chairman, Family & Community Medicine.